Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (IT:1BMY)
:1BMY
Earnings Data
Report Date
Feb 05, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
1.39Last Year’s EPS
1.44Same Quarter Last Year
Based on 19 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong growth in the portfolio, increased revenue guidance, and successful business development activities. However, there remain challenges with the adoption of new products like Cobenfy and the uncertainty surrounding IRA negotiations.Company Guidance
Strong Growth Portfolio Performance
Sales increased 17% year-over-year, driven by multiple products including IO portfolio, Reblozyl, Camzyos, and Breyanzi. Four products are now annualizing over $1 billion in sales.
Increased Revenue Guidance
Full year revenue guidance raised by $750 million at the midpoint to a range of $47.5 billion to $48 billion.
Positive Clinical and Regulatory Milestones
Several milestones achieved, including breakthrough therapy designation for iza-bren and Fast Track designation for anti-tau antibody.
Business Development Initiatives
Recent acquisition of Orbital Therapeutics and partnership with SystImmune, enhancing the cell therapy franchise and RNA technology platform.
Progress in Cost Management
Operating expenses decreased by approximately $100 million to roughly $4.2 billion compared to the same period last year, achieving significant cost savings.
IT:1BMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IT:1BMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | €36.84 | €39.02 | +5.92% |
Aug 01, 2025 | €37.91 | €37.44 | -1.24% |
Apr 24, 2025 | €41.26 | €41.51 | +0.60% |
Feb 06, 2025 | €55.32 | €54.59 | -1.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bristol-Myers Squibb (IT:1BMY) report earnings?
Bristol-Myers Squibb (IT:1BMY) is schdueled to report earning on Feb 05, 2026, Before Open (Confirmed).
What is Bristol-Myers Squibb (IT:1BMY) earnings time?
Bristol-Myers Squibb (IT:1BMY) earnings time is at Feb 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Bristol-Myers Squibb stock?
The P/E ratio of Bristol-Myers Squibb is N/A.
What is IT:1BMY EPS forecast?
IT:1BMY EPS forecast for the fiscal quarter 2025 (Q4) is 1.39.
